[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604877":3},{"organization":4,"armGroups":7,"interventions":39,"overallOfficials":45,"centralContacts":50,"locations":56,"responsibleParty":311,"collaborators":45,"id":313,"slug":314,"hasResults":315,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":319,"eligibilityCriteria":320,"healthyVolunteers":315,"sex":321,"minAge":322,"maxAge":45,"enrollmentInfo":323,"targetDuration":45,"studyType":326,"phases":327,"briefSummary":330,"conditions":331,"keywords":335,"overallStatus":59,"whyStopped":45,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":350},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8,14,18,22,26,30,34],{"label":9,"type":10,"description":11,"interventionNames":12},"Module 1: AZD3632 dose 1","EXPERIMENTAL","Participants will receive AZD3632 (dose 1) through the treatment period.",[13],"Drug: AZD3632",{"label":15,"type":10,"description":16,"interventionNames":17},"Module 1: AZD3632 dose 2","Participants will receive AZD3632 (dose 2) through the treatment period.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Module 1: AZD3632 dose 3","Participants will receive AZD3632 (dose 3) through the treatment period.",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Module 1: AZD3632 dose 4","Participants will receive AZD3632 (dose 4) through the treatment period.",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"Module 1: AZD3632 dose 5","Participants will receive AZD3632 (dose 5) through the treatment period.",[13],{"label":31,"type":10,"description":32,"interventionNames":33},"Module 1: AZD3632 dose 6","Participants will receive AZD3632 (dose 6) through the treatment period.",[13],{"label":35,"type":10,"description":36,"interventionNames":37},"Module 2: AZD3632 + posaconazole","Participants will receive AZD3632 alone, then will receive AZD3632 in combination with posaconazole through treatment period.",[13,38],"Drug: Posaconazole",[40,46],{"type":41,"name":42,"description":43,"armGroupLabels":44,"otherNames":45},"DRUG","AZD3632","AZD3632 will be administered orally.",[9,15,19,23,27,31,35],null,{"type":41,"name":47,"description":48,"armGroupLabels":49,"otherNames":45},"Posaconazole","Posaconazole will be administered orally.",[35],[51],{"name":52,"role":53,"phone":54,"phoneExt":45,"email":55},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[57,71,80,89,97,107,116,126,134,145,154,164,174,177,185,193,201,209,219,227,237,245,253,262,267,272,282,290,295,303],{"facility":58,"status":59,"city":60,"state":61,"zip":62,"country":63,"countryCode":64,"cosmosGeoPoint":65,"geoPoint":70,"contacts":45},"Research Site","RECRUITING","Decatur","Illinois","62526","United States","US",{"type":66,"coordinates":67},"Point",[68,69],-88.9548,39.84031,{"lat":69,"lon":68},{"facility":58,"status":72,"city":73,"state":73,"zip":74,"country":63,"countryCode":64,"cosmosGeoPoint":75,"geoPoint":79,"contacts":45},"NOT_YET_RECRUITING","New York","10065",{"type":66,"coordinates":76},[77,78],-74.00597,40.71427,{"lat":78,"lon":77},{"facility":58,"status":72,"city":81,"state":82,"zip":83,"country":63,"countryCode":64,"cosmosGeoPoint":84,"geoPoint":88,"contacts":45},"Chapel Hill","North Carolina","27599",{"type":66,"coordinates":85},[86,87],-79.05584,35.9132,{"lat":87,"lon":86},{"facility":58,"status":59,"city":90,"state":82,"zip":91,"country":63,"countryCode":64,"cosmosGeoPoint":92,"geoPoint":96,"contacts":45},"Durham","27705",{"type":66,"coordinates":93},[94,95],-78.89862,35.99403,{"lat":95,"lon":94},{"facility":58,"status":98,"city":99,"state":100,"zip":101,"country":63,"countryCode":64,"cosmosGeoPoint":102,"geoPoint":106,"contacts":45},"SUSPENDED","Portland","Oregon","97239",{"type":66,"coordinates":103},[104,105],-122.67621,45.52345,{"lat":105,"lon":104},{"facility":58,"status":59,"city":108,"state":109,"zip":110,"country":63,"countryCode":64,"cosmosGeoPoint":111,"geoPoint":115,"contacts":45},"Houston","Texas","77030",{"type":66,"coordinates":112},[113,114],-95.36327,29.76328,{"lat":114,"lon":113},{"facility":58,"status":98,"city":117,"state":45,"zip":118,"country":119,"countryCode":120,"cosmosGeoPoint":121,"geoPoint":125,"contacts":45},"Fitzroy","3065","Australia","AU",{"type":66,"coordinates":122},[123,124],144.97833,-37.79839,{"lat":124,"lon":123},{"facility":58,"status":98,"city":127,"state":45,"zip":128,"country":119,"countryCode":120,"cosmosGeoPoint":129,"geoPoint":133,"contacts":45},"Perth","WA 6000",{"type":66,"coordinates":130},[131,132],115.8614,-31.95224,{"lat":132,"lon":131},{"facility":58,"status":98,"city":135,"state":136,"zip":137,"country":138,"countryCode":139,"cosmosGeoPoint":140,"geoPoint":144,"contacts":45},"Toronto","Ontario","M5G 2M9","Canada","CA",{"type":66,"coordinates":141},[142,143],-79.39864,43.70643,{"lat":143,"lon":142},{"facility":58,"status":98,"city":146,"state":147,"zip":148,"country":138,"countryCode":139,"cosmosGeoPoint":149,"geoPoint":153,"contacts":45},"Montreal","Quebec","H3T 1E2",{"type":66,"coordinates":150},[151,152],-73.58781,45.50884,{"lat":152,"lon":151},{"facility":58,"status":59,"city":155,"state":45,"zip":156,"country":157,"countryCode":158,"cosmosGeoPoint":159,"geoPoint":163,"contacts":45},"Copenhagen","2100","Denmark","DK",{"type":66,"coordinates":160},[161,162],12.56553,55.67594,{"lat":162,"lon":161},{"facility":58,"status":59,"city":165,"state":45,"zip":166,"country":167,"countryCode":168,"cosmosGeoPoint":169,"geoPoint":173,"contacts":45},"Dresden","01307","Germany","DE",{"type":66,"coordinates":170},[171,172],13.73832,51.05089,{"lat":172,"lon":171},{"facility":58,"status":59,"city":175,"state":45,"zip":176,"country":167,"countryCode":168,"cosmosGeoPoint":45,"geoPoint":45,"contacts":45},"Frankfurt A. Main","60590",{"facility":58,"status":59,"city":178,"state":45,"zip":179,"country":167,"countryCode":168,"cosmosGeoPoint":180,"geoPoint":184,"contacts":45},"Halle","06097",{"type":66,"coordinates":181},[182,183],11.97947,51.48158,{"lat":183,"lon":182},{"facility":58,"status":59,"city":186,"state":45,"zip":187,"country":167,"countryCode":168,"cosmosGeoPoint":188,"geoPoint":192,"contacts":45},"Heidelberg","69120",{"type":66,"coordinates":189},[190,191],8.69079,49.40768,{"lat":191,"lon":190},{"facility":58,"status":59,"city":194,"state":45,"zip":195,"country":167,"countryCode":168,"cosmosGeoPoint":196,"geoPoint":200,"contacts":45},"München","81377",{"type":66,"coordinates":197},[198,199],13.31243,51.60698,{"lat":199,"lon":198},{"facility":58,"status":59,"city":202,"state":45,"zip":203,"country":167,"countryCode":168,"cosmosGeoPoint":204,"geoPoint":208,"contacts":45},"Ulm","89081",{"type":66,"coordinates":205},[206,207],9.99155,48.39841,{"lat":207,"lon":206},{"facility":58,"status":59,"city":210,"state":45,"zip":211,"country":212,"countryCode":213,"cosmosGeoPoint":214,"geoPoint":218,"contacts":45},"Bologna","40138","Italy","IT",{"type":66,"coordinates":215},[216,217],11.33875,44.49381,{"lat":217,"lon":216},{"facility":58,"status":59,"city":220,"state":45,"zip":221,"country":212,"countryCode":213,"cosmosGeoPoint":222,"geoPoint":226,"contacts":45},"Ravenna","48121",{"type":66,"coordinates":223},[224,225],12.20121,44.41344,{"lat":225,"lon":224},{"facility":58,"status":59,"city":228,"state":45,"zip":229,"country":230,"countryCode":231,"cosmosGeoPoint":232,"geoPoint":236,"contacts":45},"Bunkyō City","113-8677","Japan","JP",{"type":66,"coordinates":233},[234,235],139.4217,35.5331,{"lat":235,"lon":234},{"facility":58,"status":72,"city":238,"state":45,"zip":239,"country":230,"countryCode":231,"cosmosGeoPoint":240,"geoPoint":244,"contacts":45},"Kashiwa","277-8577",{"type":66,"coordinates":241},[242,243],139.97732,35.86224,{"lat":243,"lon":242},{"facility":58,"status":59,"city":246,"state":45,"zip":247,"country":230,"countryCode":231,"cosmosGeoPoint":248,"geoPoint":252,"contacts":45},"Okayama","700-8558",{"type":66,"coordinates":249},[250,251],133.93333,34.65,{"lat":251,"lon":250},{"facility":58,"status":59,"city":254,"state":45,"zip":255,"country":256,"countryCode":45,"cosmosGeoPoint":257,"geoPoint":261,"contacts":45},"Seoul","06351","South Korea",{"type":66,"coordinates":258},[259,260],126.9784,37.566,{"lat":260,"lon":259},{"facility":58,"status":59,"city":254,"state":45,"zip":263,"country":256,"countryCode":45,"cosmosGeoPoint":264,"geoPoint":266,"contacts":45},"06591",{"type":66,"coordinates":265},[259,260],{"lat":260,"lon":259},{"facility":58,"status":59,"city":254,"state":45,"zip":268,"country":256,"countryCode":45,"cosmosGeoPoint":269,"geoPoint":271,"contacts":45},"110-744",{"type":66,"coordinates":270},[259,260],{"lat":260,"lon":259},{"facility":58,"status":59,"city":273,"state":45,"zip":274,"country":275,"countryCode":276,"cosmosGeoPoint":277,"geoPoint":281,"contacts":45},"Edinburgh","EH4 2XU","United Kingdom","UK",{"type":66,"coordinates":278},[279,280],-3.19648,55.95206,{"lat":280,"lon":279},{"facility":58,"status":72,"city":283,"state":45,"zip":284,"country":275,"countryCode":276,"cosmosGeoPoint":285,"geoPoint":289,"contacts":45},"London","EC1A 7BE",{"type":66,"coordinates":286},[287,288],-0.12574,51.50853,{"lat":288,"lon":287},{"facility":58,"status":59,"city":283,"state":45,"zip":291,"country":275,"countryCode":276,"cosmosGeoPoint":292,"geoPoint":294,"contacts":45},"SE5 9RS",{"type":66,"coordinates":293},[287,288],{"lat":288,"lon":287},{"facility":58,"status":59,"city":296,"state":45,"zip":297,"country":275,"countryCode":276,"cosmosGeoPoint":298,"geoPoint":302,"contacts":45},"Manchester","M20 4BX",{"type":66,"coordinates":299},[300,301],-2.23743,53.48095,{"lat":301,"lon":300},{"facility":58,"status":98,"city":304,"state":45,"zip":305,"country":275,"countryCode":276,"cosmosGeoPoint":306,"geoPoint":310,"contacts":45},"Newcastle","NE7 7DN",{"type":66,"coordinates":307},[308,309],-5.88979,54.21804,{"lat":309,"lon":308},{"type":312,"investigatorFullName":45,"investigatorTitle":45,"investigatorAffiliation":45,"oldNameTitle":45,"oldOrganization":45},"SPONSOR","100604877","phase-1-study-of-azd3632-monotherapy-or-in-combination-with-anticancer-agents-in-participants-with-advanced-haematologic-malignancies-with-kmt2ar-npm1m-or-other-genotypes-associated-with-hox-overexpression-100604877",false,"NCT07155226","Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression","A Modular Phase I\u002FII, Open-label, Multi-Centre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression","MOMENTUM","Key Inclusion Criteria:\n\nCore criteria:\n\n* Adequate organ function.\n* Contraceptive use by participants or participant partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n\nModule 1:\n\n* Advanced haematologic malignancy - a) for dose escalation - diagnosis of acute leukemia or myelodysplastic neoplasia (MDS) and harbouring one of the genetic alterations per local testing associated with upregulation of HOX; b) for Backfill - diagnosis of harbouring a KMT2Ar or NPM1m per local testing.\n* Participants must have measurable disease that is relapsed\u002Frefractory to conventional therapies known to be effective for their disease and not have any available approved therapies.: a) Relapsed and primary refractory acute leukaemia after standard of care therapy including but not limited to 2 cycles of intensive chemotherapy, hypomethylating agent (HMA) monotherapy, or HMA combinations such as HMA\u002Fvenetoclax.; b) Relapsed and primary refractory MDS is defined by ≥ 5% blasts in the bone marrow and\u002For persistence of peripheral blasts after treatment with at least 2 cycles of HMA. Participants ineligible for the treatment with an HMA and without any other standard of care (SoC) options are allowed to enrol; c) White blood cell count below 25,000\u002FμL. Participants may receive cytoreduction per protocol-specified criteria; d) Performance status: Eastern Cooperative Operative Group (ECOG) ≤ 2; e) Life expectancy: ≥ 8 weeks.\n\nModule 2:\n\n* Participants must have measurable disease that is relapsed\u002Frefractory to conventional therapies known to be effective for their disease and not have any available approved therapies.: a) Relapsed and primary refractory acute leukaemia after standard of care therapy including but not limited to 2 cycles of intensive chemotherapy, HMA monotherapy, or HMA combinations such as HMA\u002Fvenetoclax.; b) Relapsed and primary refractory MDS is defined by ≥ 5% blasts in the bone marrow and\u002For persistence of peripheral blasts after treatment with at least 2 cycles of HMA. Participants ineligible for the treatment with an HMA and without any other SoC options are allowed to enrol; c) White blood cell count below 25,000\u002FμL. Participants may receive cytoreduction per protocol-specified criteria; d) Performance status: ECOG ≤ 2; e) Life expectancy: ≥ 8 weeks.\n\nKey Exclusion Criteria:\n\nCore criteria:\n\n* Participants with Burkitt lymphoma\u002Fleukaemia or Acute Promyelocytic Leukaemia.\n* Active testicular or active central nervous system (CNS) (\\> CNS1 or radiographic) involvement by leukaemia.\n* Unresolved treatment-related toxicities Grade ≥ 2 from prior therapy.\n* Abnormal levels of potassium or magnesium prior to first dose of AZD3632.\n\nModule 1:\n\n* Receipt of non-CNS radiation therapy within 2 weeks and of CNS radiation within 8 weeks of the first scheduled dose.\n* Receipt of any investigational or non-investigational anticancer agents, including non-biologic agents, biologic agents and\u002For prior treatment other menin inhibitors (backfill participants only).\n* For nested food effect participants - diagnosis of diabetes mellitus (Type I or Type II).\n\nModule 2:\n\n* Receipt of any non-investigational anticancer agents, including non-biologic agents and\u002For biologic agents or receipt of non-CNS or CNS radiation therapy.\n* Participants for whom treatment with posaconazole is contraindicated per the local prescribing information.","ALL","16 Years",{"count":324,"type":325},84,"ESTIMATED","INTERVENTIONAL",[328,329],"PHASE1","PHASE2","The purpose of this study is to understand the safety, tolerability, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of orally administered AZD3632 in participants with advanced haematologic malignancies with KMT2Ar, NPM1m, or other genotypes associated with homeobox (HOX) overexpression.",[332,333,334],"Acute Lymphoblastic Leukaemia","Acute Myeloid Leukaemia","Higher-risk Myelodysplastic Syndromes",[336,337,338,339,340],"Myelodysplastic Syndromes","Menin inhibitor","Anti-leukaemic activity","Anti-fungal agent","HOX overexpression.","2026-06-16",{"date":343,"type":344},"2026-06-17","ACTUAL",{"date":346,"type":344},"2026-01-09",{"date":348,"type":325},"2029-02-15",{"name":5,"class":6},30]